Using drug treatment to prevent sexually transmitted infections in women who use drugs
Drug Treatment as Disease Prevention: Reducing Sexually Transmitted Infection Risk among Women Who Use Drugs
This study is looking at how getting help for drug use can lower the chances of women getting sexually transmitted infections (STIs), especially for those who don’t inject drugs, and it aims to find better ways to support these women in accessing treatment.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Central Florida NIH-funded |
| Lab location | 1 site (Orlando, United States) |
| Project ID | NIH-11085056 on NIH RePORTER |
What this research studies
This research investigates how drug treatment can help reduce the risk of sexually transmitted infections (STIs) among women who use drugs. It focuses on understanding the relationship between drug treatment and sexual risk behaviors, particularly in women who may not inject drugs. By analyzing data from a previous study, the research aims to identify how drug treatment can serve as a preventive measure against STIs and explore the various factors that affect access to treatment. The goal is to uncover new intervention strategies that could improve health outcomes for this vulnerable population.
Who could benefit from this research
Good fit: Ideal candidates for this research are women who use drugs, including those who may or may not inject substances.
Not a fit: Patients who do not use drugs or who are not at risk for sexually transmitted infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective strategies for preventing STIs among women who use drugs, ultimately improving their health and well-being.
How similar studies have performed: Previous research has shown that drug treatment can reduce the risk of blood-borne infections like HIV and HCV, but this approach for STIs in women is less explored, making this research relatively novel.
Where this research is happening
Orlando, United States
- University of Central Florida — Orlando, United States (Active)
Researchers
- Principal investigator: Scheidell, Joy Danielle — University of Central Florida
- Study coordinator: Scheidell, Joy Danielle
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.